India Biosimilar Market Growth, Share, And Trends Report 2025-2033

India Biosimilar Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 17.38% (2025-2033)

India biosimilar industry is growing at a rapid pace owing to the rising demand for affordable biologics and favorable regulation. Research and development and manufacturing are also fueling market growth. According to the latest report by IMARC Group, the India biosimilar market size reached USD 866.2 million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

India Biosimilar Trends and Drivers:

The India biosimilar market is growing quickly. This rise comes from the need for affordable biologic therapies. It also includes a solid range of biosimilar products and supportive government policies. Biosimilars provide a cost-effective option for many patients facing chronic diseases. These conditions include diabetes, cancer, and autoimmune disorders. They serve as a cheaper alternative to costly originator biologics. India is a global leader in biosimilar production. This is thanks to its strong pharmaceutical manufacturing. Key biotech hubs like Hyderabad and Bengaluru drive this success. Biocon, Dr. Reddy’s, and Intas Pharmaceuticals lead the way. They use advanced technologies and form strategic partnerships to grow their biosimilar portfolios. The market gains from quicker approvals by the CDSCO. This helps boost innovation, too. More healthcare spending and improved insurance make biosimilars more accessible to many. Challenges include strict quality standards, global competition, and low awareness.

A key trend in the India biosimilar market is the focus on export opportunities. This is especially true in regulated markets like the US and Europe. Indian biosimilar makers are investing in clinical trials and meeting regulatory standards. This helps them access high-value markets. For instance, Biocon’s trastuzumab and bevacizumab biosimilars have seen success abroad. Hospitals and government programs, such as Ayushman Bharat, back the use of biosimilars in India. These efforts aim to provide affordable healthcare to underserved populations. Contract manufacturing and research partnerships with large companies help the market grow. Digital advancements are being explored too. For example, AI-driven drug development and blockchain technology enhance supply chain transparency. Still, pricing pressures and the need for strong post-marketing surveillance are key concerns. These are essential for ensuring long-term safety and efficacy. As the market evolves, education campaigns are crucial. They can clear up myths about biosimilars. This helps build trust with healthcare providers and patients. India’s biosimilar market combines innovation, affordability, and global reach. This mix will shape the future of biologic therapies around the world.

Download a sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

India Biosimilar Industry Segmentation:

The report has segmented the market into the following categories:

Molecule Insights:

• Infliximab

• Insulin Glargine

• Epoetin Alfa

• Etanercept

• Filgrastim

• Somatropin

• Rituximab

• Follitropin Alfa

• Adalimumab

• Pegfilgrastim

• Trastuzumab

• Bevacizumab

• Others

Indication Insights:

• Auto-Immune Diseases

• Blood Disorder

• Diabetes

• Oncology

• Growth Deficiency

• Female Infertility

• Others

Manufacturing Type Insights:

• In-house Manufacturing

• Contract Manufacturing

Regional Insights:

• North India

• West and Central India

• South India

• East and Northeast India

Competitive Landscape:

The competitive landscape of the industry has also been examined, along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2019-2024)

• Market Outlook (2025-2033)

• COVID-19 Impact on the Market

• Porter’s Five Forces Analysis

• Strategic Recommendations

• Historical, Current, and Future Market Trends

• Market Drivers and Success Factors

• SWOT Analysis

• Structure of the Market

• Value Chain Analysis

• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St., Brooklyn, NY 11249, USA 

Email: sales@imarcgroup.com 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145